INSPIRE: a Multi-Cancer Early Detection Study

Launched by SINGLERA GENOMICS INC. · May 28, 2024

Keywords

ClinConnect Summary

The INSPIRE trial is a research study focused on finding a better way to detect multiple types of cancer early, including lung, breast, and colorectal cancers, among others. The study aims to develop a special machine learning tool that can analyze blood samples from people with newly diagnosed cancer and those who do not have cancer. By comparing these two groups, researchers hope to improve early detection methods, which can lead to better treatment outcomes.

To participate in this trial, individuals must be between 40 and 75 years old. Those with a confirmed cancer diagnosis can join the "case arm," while healthy individuals without cancer can join the "control arm." Participants will need to provide a blood sample and consent to follow the study’s procedures. It's important to note that certain health conditions or recent treatments may prevent someone from joining, so potential participants should discuss their eligibility with the study team. This study is currently recruiting participants and offers a chance to contribute to important cancer research that could help save lives in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for Case Arm Participants:
• • 40-75 years old
• • Clinically and/or pathologically diagnosed cancer
• • No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.
• • Able to provide a written informed consent and willing to comply with all part of the protocol procedures
• Exclusion Criteria for Case Arm Participants:
• • Pregnancy or lactating women
• • Known prior or current diagnosis of other types of malignancies comorbidities
• • Have participated in an "interventional" clinical trial within the past 30 days and have taken the experimental drug;
• • Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
• • Recipients of blood transfusion within 30 days prior to screen
• • Recipients of therapy in past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide
• • Failure to collect blood on time according to plan
• • The blood sample does not meet the requirements
• Inclusion Criteria for Control Arm Participants:
• • 40-75 years old
• • Without confirmed cancer diagnosis
• • Able to provide a written informed consent and willing to comply with all part of the protocol procedures
• Exclusion Criteria for Control Arm Participants:
• • Pregnancy or lactating women
• • No previous history of malignancy in other sites
• • Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
• • Recipients of blood transfusion within 30 days prior to screen
• • Recipients of therapy in the past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide
• • Unsuitable for this trial determined by the researchers